If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Advances in Psychotherapy for Posttraumatic Stress Disorder, 1
By Alison Krauss, Ena Begovic, Kristina Harper, and Ellen J. Teng
Introduction, 1
Overview of evidence-based treatments for posttraumatic stress disorder, 2
Prolonged Exposure Therapy, 2
Cognitive Processing Therapy, 2
Eye Movement Desensitization and Reprocessing, 4
Cognitive Behavioral Therapy, 4
Brief Eclectic Psychotherapy for Posttraumatic Stress Disorder, 4
Narrative Exposure Therapy, 5
Intensive and brief posttraumatic stress disorder treatment approaches, 5
Intensive Trauma-Focused Treatments, 5
Brief Treatments, 5
Technology-assisted delivery of posttraumatic stress disorder treatment, 6
Internet-Based Interventions, 6
Mobile Applications, 6
Video Telehealth, 7
Practice considerations, 7
Clinics care points, 8
Advances in Psychotherapy for Eating Disorders, 13
By Cody Staples, William Grunewald, April R. Smith, and Diana Rancourt
Background, 13
Current evidence, 13
Psychotherapy for Anorexia Nervosa, 14
Psychotherapy for Bulimia Nervosa, 14
Psychotherapy for Binge Eating Disorder, 15
Psychotherapy for Avoidant/Restrictive Food Intake Disorder, 16
Factors Predicting Treatment Outcomes, 16
Telehealth, Online Interventions, and Just-in-Time-Adaptive Interventions, 16
Other Promising Approaches, 17
Cue exposure and response prevention, 17
Appetite awareness training, 17
Biofeedback-focused approaches, 17
Unified protocol, 17
Understudied Populations, 17
Discussion, 18
Summary, 19
Clinics care points, 19
Is Less Really More? Analysis of Brief, Intensive Treatments for Obsessive-Compulsive Disorder, 25
By Bradley C. Riemann, Sarah J. David, Nicholas R. Farrell, and Brenda E. Bailey
Exposure-based treatment for obsessive-compulsive disorder: massed versus spaced models, 26
Brief intensive treatments for pediatric obsessive-compulsive disorder, 27
Brief intensive treatment for adult obsessive-compulsive disorder, 28
Strength of data, 30
Theoretic basis for findings of brief exposure and response prevention models, 31
Summary and future directions in brief, intensive treatments for obsessive-compulsive disorder, 32
Disclosure, 33
Third-Wave Cognitive Behavioral Therapy for Obsessive Compulsive Disorder?: A Promising Approach if It Includes Exposure, 37
By Erika S. Trent, Andrew G. Guzick, Andres G. Viana, and Eric A. Storch
Introduction/background, 37
Rationale, 38
Approach, 39
Current evidence, 39
Acceptance and Commitment Therapy, 39
Mindfulness-Based Therapies, 45
Metacognitive Therapy, 46
Discussion, 47
Recommendations, 47
Future Directions, 48
Summary, 48
Clinics care points, 48
Disclosure, 48
Suicide Research
Digital Technology for Suicide Prevention, 53
By Jordan M. Braciszewski
Introduction, 53
Gaps in Current Approaches to Identification and Treatment, 53
Leveraging Digital Technologies to Address a Major Public Health Problem, 54
Current evidence, 55
Technology-Based Screening, 55
Self-Guided Internet-Based Approaches, 55
Mobile Applications, 55
Data-Driven Approaches to Identification, 57
Adoption of digital strategies, 57
Future directions, 58
Summary and recommendations for practitioners, 59
Clinics care points, 60
Disclosure, 60
Identifying People at Risk for Suicide: Implementation of Screening for the Zero Suicide Initiative in Large Health Systems, 67
By Karen J. Coleman, Christine C. Stewart, Cambria Bruschke, Jean P. Flores, Andrea Altschuler, Arne Beck, Frances L. Lynch, Ashli A. Owen-Smith, Julie E. Richards, Rebecca Rossom, Gregory E. Simon, Stacy Sterling, and Brian K. Ahmedani
Introduction, 68
Methods, 69
Study Design, 69
Settings and Population, 69
Zero Suicide Care Improvements, 69
Data and Sources for Evaluation, 70
Analyses, 70
Results, 70
Discussion, 72
Considerations for Implementation, 73
Limitations, 73
Future Directions, 74
Clinics care points, 74
Disclosure, 74
Lethal Means Safety Approaches for Suicide Prevention, 77
By Leslie Barnard, Ali Rowhani-Rahbar, and Marian E. Betz
Background, 77
Framework for prevention efforts, 78
Societal, 78
Community, 80
Relationship, 81
Individual, 82
Challenges for lethal means safety approaches, 83
Future directions, 84
Summary, 85
Clinics care points, 85
Disclosure, 85
Women's Mental Health
Treatment of Premenstrual Dysphoric Disorder (PMDD): Advances and Challenges, 91
By Liisa Hantsoo and Julia Riddle
Introduction, 91
Diagnosis Informs Treatment, 91
Premenstrual dysphoric disorder treatment, 92
Selective Serotonin Reuptake Inhibitors, 92
Hormonal Contraceptives, 93
Psychotherapy, 93
Gonadotropin-Releasing Hormone Medications, 93
Surgical Oophorectomy, 94
Treatment challenges, 94
Medication Nonresponse, 94
Comorbidities, 94
Reproductive Transitions, 100
Recent developments in treatment, 100
Neuroactive Steroid-Based Pharmacotherapy, 100
Internet-Based Cognitive-Behavioral Therapy, 101
Discussion, 101
Summary, 101
Clinics care points, 101
Disclosure, 102
Novel Neurosteroid Pharmaceuticals: Implications Across a Woman's Lifecycle, 107
By Leah C. Susser, Clare Swanson, and Alison D. Hermann
Introduction, 107
Background, 107
Perinatal depression, 108
Brexanolone, 108
Zuranolone (SAGE-217), 112
Ganaxolone, 112
SGE-516, 112
Premenstrual dysphoric disorder, 113
Dutasteride, 113
Sepranolone, 113
Ulipristal acetate (UPA), 114
Perimenopausal depression, 114
Other periods of a woman’s life, 114
Limitations and future directions for reproductive depression treatment with neuroactive steroids, 114
Summary, 115
Clinics care points, 115
Disclosure, 115
Sports Psychiatry
Mental Health in Youth Athletes: A Clinical Review, 119
By Courtney C. Walton, Simon Rice, R.I. (Vana) Hutter, Alan Currie, Claudia L. Reardon, and Rosemary Purcell
Introduction, 119
Young people can thrive through sport, 120
Mental health and related stressors in youth sport, 120
Pressure to Perform and Perfectionism, 120
Burnout and Early Specialization, 123
Peer and Parental Conflict, 123
Abuse and Maltreatment, 123
Injury and Concussion, 124
Body Image and Weight Concerns, 124
Disrupted Sleep, 124
Assessment of youth athletes, 125
Athlete Resistance and Mental Health Stigma, 125
Assessment Tools, 125
Collateral Information, 126
Treatment of youth athletes, 126
Psychological Approaches, 126
Pharmacologic Considerations, 126
Summary, 129
Disclosure, 129
Diagnosis and Management of Substance Use Disorders in Athletes, 135
By Pamela Walters, Bradley Hillier, Filippo Passetti, Anju Soni, and Ian Treasaden
Introduction, 135
Background, 135
Neurobiological Correlates: Athletes and Addictive Behaviors, 136
Diagnostic Criteria for Substance Use Disorder, 136
Assessment, 136
Pharmacologic interventions, 136
Background, 136
Alcohol, 136
Cannabis, 140
Nicotine, 140
Stimulants, 140
Opioids, 141
Psychosocial Interventions, 141
Summary, 141
Disclosure, 142
Sex Differences in Psychiatric Diagnosis and Management of Athletes, 145
By Danielle Kamis
Sex differences in psychopathology, 145
Mood Disorders, 145
Anxiety Disorders, 145
The Female Athletic Triad, 145
Eating Disorders, 146
Substance Use, 146
Clinical Case, 147
Summary and future direction, 147
Disclosure, 147
Anxiety Disorders in Athletes: A Clinical Review, 149
By Claudia L. Reardon, Paul Gorczynski, Brian Hainline, Mary Hitchcock, Rosemary Purcell, Simon Rice, and Courtney Walton
Introduction/background, 149
General information, 150
Generalized anxiety disorder, 150
Panic disorder, 150
Social anxiety disorder, 151
Obsessive-compulsive disorder, 151
Competitive performance anxiety, 152
Other anxiety-related disorders, 153
General principles of diagnosis and management, 153
Discussion, 156
Summary, 157
Clinics care points, 157
Disclosure, 157
Neurosciences
Neuropsychiatric Manifestations of COVID-19: A Review, 161
By Moein Foroughi, Rishab Gupta, Amvrine Ganguly, Junaid Mirza, and Aryandokht Fotros
Introduction, 161
Methods, 162
COVID-19 and delirium, 162
COVID-19 and cognitive deficits, 163
COVID-19 and psychosis, 163
COVID-19 and depression, 164
COVID-19 and suicide, 164
COVID-19 and mania, 165
COVID-19 and anxiety, 165
Proposed neurobiological mechanisms, 166
Neuropsychiatric adverse effects of medications used to treat COVID-19, 166
Psychosocial factors associated with COVID-19 as risk factors for neuropsychiatric disorders, 167
Discussion, 167
Disclosure, 169
The Use of Repetitive Transcranial Magnetic Stimulation in Depression and Other Psychiatric Disorders; the Knowns and the Unknowns, 173
By Mandana Modirrousta, Benjamin P. Meek, and Mohamed Abo Aoun
Introduction, 173
Patient factors, 174
Disease factors, 175
Treatment-specific factors, 175
Frequency, 175
Number of Pulses, 175
Stimulation Intensity, 176
Stimulation Target, 176
Duration of Treatment, 177
Side Effects, 177
Pre-TMS Evaluation, 177
rTMS in other psychiatric disorders, 178
Obsessive Compulsive Disorder (OCD), 178
Schizophrenia, 178
Substance Use Disorder, 178
Eating Disorders, 178
Anxiety Disorders, 178
Posttraumatic Stress Disorder (PTSD), 178
Summary, 178
Clinics care points, 179
Disclosure, 179
Advances in Depression Management: Multifunctional Antidepressant Medications, 185
By Michael Ingram, Gerald Maguire, and Stephen M. Stahl
Introduction, 185
Multifunctional antidepressant mechanisms, 186
Monoamine reuptake inhibition, 186
Combining types of monoamine reuptake inhibition for multifunctional treatment of depression, 186
Combining norepinephrine and dopamine reuptake inhibition, 189
Combining serotonin reuptake inhibition with agonist or antagonist actions at multiple serotonin receptor subtypes, 192
Combining serotonin reuptake inhibition with serotonin receptor antagonism, 195
Norepinephrine antagonism and mirtazapine, 199
Should a combination of antidepressant mechanisms be the standard for treating unipolar depression?, 200
Summary, 202
Disclosures, 202
Education
Dementia After Traumatic Brain Injury: From Neural Mechanisms to Psychiatry, 205
By Vassilis E. Koliatsos, Vani Rao, and Athanasios S. Alexandris
The problem and its significance, 205
The typology of chronic traumatic brain injury, 206
Traumatic Brain Injury: Transient Versus Chronic Disease, 206
Focal Contusions, 207
Acceleration Injuries: Diffuse Axonal Injury, 207
Repetitive Mild Traumatic Brain Injury and Chronic Traumatic Encephalopathy, 207
Blast Injury to Brain, 208
Select mechanisms of degeneration after traumatic brain injury, 208
Traumatic Axonopathy and Disconnection—the Importance of the White Matter, 208
Protein Aggregation (Proteinopathy), 209
Chronic traumatic brain injury as neuropsychiatric disease, 209
Clinical Presentations, 209
Brain-Behavior Correlations, 210
Cognitive impairments and dementia after traumatic brain injury, 211
Overview, 211
Neurodegenerative Disease Specific to Traumatic Brain Injury: the Problem of Athletic Concussions and Chronic Traumatic Encephalopathy, 212
Traumatic Brain Injury as a Risk Factor for Neurodegeneration Other Than Chronic Traumatic Encephalopathy, 214
Summary, 214
Learning Psychiatry: Then and Now, 219
By Lisa MacLean and Deepak Prabhakar
Introduction, 219
Discussion, 220
Training Attitudes, 220
Culture of Medicine, 221
Assessment of Clinician Well-Being, 222
Advances in Technology, 222
Supervision Challenges, 223
The Current and Future Practice of Psychiatry, 223
Summary, 226
Disclosure, 226
Clinical Psychology Training: Past, Present, and Future, 229
By Lisa R. Miller-Matero, Nora Coultis, Anissa J. Maffett, Brittany A. Haage, Sai B. Narotam, and Kellie M. Martens
Introduction, 229
Specialties and board certification, 229
Training in Specialties and Board Certification, 230
Future Directions, 231
Integrated care, 231
Training in Integrated Care, 231
Future Directions, 232
Technology, 232
Training in Technology, 232
Future Directions, 232
Multiculturalism, 233
Training in Multicultural Considerations, 233
Future Directions, 234
Summary, 234
Disclosure, 234
Integrating Book Club in Psychiatric Education, 239
Advances in Psychotherapy for Posttraumatic Stress Disorder, 1
By Alison Krauss, Ena Begovic, Kristina Harper, and Ellen J. Teng
Introduction, 1
Overview of evidence-based treatments for posttraumatic stress disorder, 2
Prolonged Exposure Therapy, 2
Cognitive Processing Therapy, 2
Eye Movement Desensitization and Reprocessing, 4
Cognitive Behavioral Therapy, 4
Brief Eclectic Psychotherapy for Posttraumatic Stress Disorder, 4
Narrative Exposure Therapy, 5
Intensive and brief posttraumatic stress disorder treatment approaches, 5
Intensive Trauma-Focused Treatments, 5
Brief Treatments, 5
Technology-assisted delivery of posttraumatic stress disorder treatment, 6
Internet-Based Interventions, 6
Mobile Applications, 6
Video Telehealth, 7
Practice considerations, 7
Clinics care points, 8
Advances in Psychotherapy for Eating Disorders, 13
By Cody Staples, William Grunewald, April R. Smith, and Diana Rancourt
Background, 13
Current evidence, 13
Psychotherapy for Anorexia Nervosa, 14
Psychotherapy for Bulimia Nervosa, 14
Psychotherapy for Binge Eating Disorder, 15
Psychotherapy for Avoidant/Restrictive Food Intake Disorder, 16
Factors Predicting Treatment Outcomes, 16
Telehealth, Online Interventions, and Just-in-Time-Adaptive Interventions, 16
Other Promising Approaches, 17
Cue exposure and response prevention, 17
Appetite awareness training, 17
Biofeedback-focused approaches, 17
Unified protocol, 17
Understudied Populations, 17
Discussion, 18
Summary, 19
Clinics care points, 19
Is Less Really More? Analysis of Brief, Intensive Treatments for Obsessive-Compulsive Disorder, 25
By Bradley C. Riemann, Sarah J. David, Nicholas R. Farrell, and Brenda E. Bailey
Exposure-based treatment for obsessive-compulsive disorder: massed versus spaced models, 26
Brief intensive treatments for pediatric obsessive-compulsive disorder, 27
Brief intensive treatment for adult obsessive-compulsive disorder, 28
Strength of data, 30
Theoretic basis for findings of brief exposure and response prevention models, 31
Summary and future directions in brief, intensive treatments for obsessive-compulsive disorder, 32
Disclosure, 33
Third-Wave Cognitive Behavioral Therapy for Obsessive Compulsive Disorder?: A Promising Approach if It Includes Exposure, 37
By Erika S. Trent, Andrew G. Guzick, Andres G. Viana, and Eric A. Storch
Introduction/background, 37
Rationale, 38
Approach, 39
Current evidence, 39
Acceptance and Commitment Therapy, 39
Mindfulness-Based Therapies, 45
Metacognitive Therapy, 46
Discussion, 47
Recommendations, 47
Future Directions, 48
Summary, 48
Clinics care points, 48
Disclosure, 48
Suicide Research
Digital Technology for Suicide Prevention, 53
By Jordan M. Braciszewski
Introduction, 53
Gaps in Current Approaches to Identification and Treatment, 53
Leveraging Digital Technologies to Address a Major Public Health Problem, 54
Current evidence, 55
Technology-Based Screening, 55
Self-Guided Internet-Based Approaches, 55
Mobile Applications, 55
Data-Driven Approaches to Identification, 57
Adoption of digital strategies, 57
Future directions, 58
Summary and recommendations for practitioners, 59
Clinics care points, 60
Disclosure, 60
Identifying People at Risk for Suicide: Implementation of Screening for the Zero Suicide Initiative in Large Health Systems, 67
By Karen J. Coleman, Christine C. Stewart, Cambria Bruschke, Jean P. Flores, Andrea Altschuler, Arne Beck, Frances L. Lynch, Ashli A. Owen-Smith, Julie E. Richards, Rebecca Rossom, Gregory E. Simon, Stacy Sterling, and Brian K. Ahmedani
Introduction, 68
Methods, 69
Study Design, 69
Settings and Population, 69
Zero Suicide Care Improvements, 69
Data and Sources for Evaluation, 70
Analyses, 70
Results, 70
Discussion, 72
Considerations for Implementation, 73
Limitations, 73
Future Directions, 74
Clinics care points, 74
Disclosure, 74
Lethal Means Safety Approaches for Suicide Prevention, 77
By Leslie Barnard, Ali Rowhani-Rahbar, and Marian E. Betz
Background, 77
Framework for prevention efforts, 78
Societal, 78
Community, 80
Relationship, 81
Individual, 82
Challenges for lethal means safety approaches, 83
Future directions, 84
Summary, 85
Clinics care points, 85
Disclosure, 85
Women's Mental Health
Treatment of Premenstrual Dysphoric Disorder (PMDD): Advances and Challenges, 91
By Liisa Hantsoo and Julia Riddle
Introduction, 91
Diagnosis Informs Treatment, 91
Premenstrual dysphoric disorder treatment, 92
Selective Serotonin Reuptake Inhibitors, 92
Hormonal Contraceptives, 93
Psychotherapy, 93
Gonadotropin-Releasing Hormone Medications, 93
Surgical Oophorectomy, 94
Treatment challenges, 94
Medication Nonresponse, 94
Comorbidities, 94
Reproductive Transitions, 100
Recent developments in treatment, 100
Neuroactive Steroid-Based Pharmacotherapy, 100
Internet-Based Cognitive-Behavioral Therapy, 101
Discussion, 101
Summary, 101
Clinics care points, 101
Disclosure, 102
Novel Neurosteroid Pharmaceuticals: Implications Across a Woman's Lifecycle, 107
By Leah C. Susser, Clare Swanson, and Alison D. Hermann
Introduction, 107
Background, 107
Perinatal depression, 108
Brexanolone, 108
Zuranolone (SAGE-217), 112
Ganaxolone, 112
SGE-516, 112
Premenstrual dysphoric disorder, 113
Dutasteride, 113
Sepranolone, 113
Ulipristal acetate (UPA), 114
Perimenopausal depression, 114
Other periods of a woman’s life, 114
Limitations and future directions for reproductive depression treatment with neuroactive steroids, 114
Summary, 115
Clinics care points, 115
Disclosure, 115
Sports Psychiatry
Mental Health in Youth Athletes: A Clinical Review, 119
By Courtney C. Walton, Simon Rice, R.I. (Vana) Hutter, Alan Currie, Claudia L. Reardon, and Rosemary Purcell
Introduction, 119
Young people can thrive through sport, 120
Mental health and related stressors in youth sport, 120
Pressure to Perform and Perfectionism, 120
Burnout and Early Specialization, 123
Peer and Parental Conflict, 123
Abuse and Maltreatment, 123
Injury and Concussion, 124
Body Image and Weight Concerns, 124
Disrupted Sleep, 124
Assessment of youth athletes, 125
Athlete Resistance and Mental Health Stigma, 125
Assessment Tools, 125
Collateral Information, 126
Treatment of youth athletes, 126
Psychological Approaches, 126
Pharmacologic Considerations, 126
Summary, 129
Disclosure, 129
Diagnosis and Management of Substance Use Disorders in Athletes, 135
By Pamela Walters, Bradley Hillier, Filippo Passetti, Anju Soni, and Ian Treasaden
Introduction, 135
Background, 135
Neurobiological Correlates: Athletes and Addictive Behaviors, 136
Diagnostic Criteria for Substance Use Disorder, 136
Assessment, 136
Pharmacologic interventions, 136
Background, 136
Alcohol, 136
Cannabis, 140
Nicotine, 140
Stimulants, 140
Opioids, 141
Psychosocial Interventions, 141
Summary, 141
Disclosure, 142
Sex Differences in Psychiatric Diagnosis and Management of Athletes, 145
By Danielle Kamis
Sex differences in psychopathology, 145
Mood Disorders, 145
Anxiety Disorders, 145
The Female Athletic Triad, 145
Eating Disorders, 146
Substance Use, 146
Clinical Case, 147
Summary and future direction, 147
Disclosure, 147
Anxiety Disorders in Athletes: A Clinical Review, 149
By Claudia L. Reardon, Paul Gorczynski, Brian Hainline, Mary Hitchcock, Rosemary Purcell, Simon Rice, and Courtney Walton
Introduction/background, 149
General information, 150
Generalized anxiety disorder, 150
Panic disorder, 150
Social anxiety disorder, 151
Obsessive-compulsive disorder, 151
Competitive performance anxiety, 152
Other anxiety-related disorders, 153
General principles of diagnosis and management, 153
Discussion, 156
Summary, 157
Clinics care points, 157
Disclosure, 157
Neurosciences
Neuropsychiatric Manifestations of COVID-19: A Review, 161
By Moein Foroughi, Rishab Gupta, Amvrine Ganguly, Junaid Mirza, and Aryandokht Fotros
Introduction, 161
Methods, 162
COVID-19 and delirium, 162
COVID-19 and cognitive deficits, 163
COVID-19 and psychosis, 163
COVID-19 and depression, 164
COVID-19 and suicide, 164
COVID-19 and mania, 165
COVID-19 and anxiety, 165
Proposed neurobiological mechanisms, 166
Neuropsychiatric adverse effects of medications used to treat COVID-19, 166
Psychosocial factors associated with COVID-19 as risk factors for neuropsychiatric disorders, 167
Discussion, 167
Disclosure, 169
The Use of Repetitive Transcranial Magnetic Stimulation in Depression and Other Psychiatric Disorders; the Knowns and the Unknowns, 173
By Mandana Modirrousta, Benjamin P. Meek, and Mohamed Abo Aoun
Introduction, 173
Patient factors, 174
Disease factors, 175
Treatment-specific factors, 175
Frequency, 175
Number of Pulses, 175
Stimulation Intensity, 176
Stimulation Target, 176
Duration of Treatment, 177
Side Effects, 177
Pre-TMS Evaluation, 177
rTMS in other psychiatric disorders, 178
Obsessive Compulsive Disorder (OCD), 178
Schizophrenia, 178
Substance Use Disorder, 178
Eating Disorders, 178
Anxiety Disorders, 178
Posttraumatic Stress Disorder (PTSD), 178
Summary, 178
Clinics care points, 179
Disclosure, 179
Advances in Depression Management: Multifunctional Antidepressant Medications, 185
By Michael Ingram, Gerald Maguire, and Stephen M. Stahl
Introduction, 185
Multifunctional antidepressant mechanisms, 186
Monoamine reuptake inhibition, 186
Combining types of monoamine reuptake inhibition for multifunctional treatment of depression, 186
Combining norepinephrine and dopamine reuptake inhibition, 189
Combining serotonin reuptake inhibition with agonist or antagonist actions at multiple serotonin receptor subtypes, 192
Combining serotonin reuptake inhibition with serotonin receptor antagonism, 195
Norepinephrine antagonism and mirtazapine, 199
Should a combination of antidepressant mechanisms be the standard for treating unipolar depression?, 200
Summary, 202
Disclosures, 202
Education
Dementia After Traumatic Brain Injury: From Neural Mechanisms to Psychiatry, 205
By Vassilis E. Koliatsos, Vani Rao, and Athanasios S. Alexandris
The problem and its significance, 205
The typology of chronic traumatic brain injury, 206
Traumatic Brain Injury: Transient Versus Chronic Disease, 206
Focal Contusions, 207
Acceleration Injuries: Diffuse Axonal Injury, 207
Repetitive Mild Traumatic Brain Injury and Chronic Traumatic Encephalopathy, 207
Blast Injury to Brain, 208
Select mechanisms of degeneration after traumatic brain injury, 208
Traumatic Axonopathy and Disconnection—the Importance of the White Matter, 208
Protein Aggregation (Proteinopathy), 209
Chronic traumatic brain injury as neuropsychiatric disease, 209
Clinical Presentations, 209
Brain-Behavior Correlations, 210
Cognitive impairments and dementia after traumatic brain injury, 211
Overview, 211
Neurodegenerative Disease Specific to Traumatic Brain Injury: the Problem of Athletic Concussions and Chronic Traumatic Encephalopathy, 212
Traumatic Brain Injury as a Risk Factor for Neurodegeneration Other Than Chronic Traumatic Encephalopathy, 214
Summary, 214
Learning Psychiatry: Then and Now, 219
By Lisa MacLean and Deepak Prabhakar
Introduction, 219
Discussion, 220
Training Attitudes, 220
Culture of Medicine, 221
Assessment of Clinician Well-Being, 222
Advances in Technology, 222
Supervision Challenges, 223
The Current and Future Practice of Psychiatry, 223
Summary, 226
Disclosure, 226
Clinical Psychology Training: Past, Present, and Future, 229
By Lisa R. Miller-Matero, Nora Coultis, Anissa J. Maffett, Brittany A. Haage, Sai B. Narotam, and Kellie M. Martens
Introduction, 229
Specialties and board certification, 229
Training in Specialties and Board Certification, 230
Future Directions, 231
Integrated care, 231
Training in Integrated Care, 231
Future Directions, 232
Technology, 232
Training in Technology, 232
Future Directions, 232
Multiculturalism, 233
Training in Multicultural Considerations, 233
Future Directions, 234
Summary, 234
Disclosure, 234
Integrating Book Club in Psychiatric Education, 239
